Financing physiocrines

aTyr Pharma Inc. could have raised more in its series D round last week, but decided to cap the financing at $49 million and instead take out a $10 million loan. The $59 million should give the company enough runway to demonstrate clinical proof of concept for its lead physiocrine program to treat rare autoimmune disorders.

The new investor in the round is an undisclosed global investment fund that invests mainly in public companies but occasionally puts money into private rounds, according to aTyr Executive Chairman and CEO John Mendlein...